drugset / Trial / NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Timeline
- Start
- 2024-04-18
- Primary completion
- 2028-06-28
- Completion
- 2032-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erdafitinib | Small molecule | — | Other |
| Comparator | Gemcitabine | Small molecule | — | Other |
| Comparator | Mitomycin C | Other / unclassified | — | Other |